Oncolys BioPharma, Inc. (4588) AI Stock Analysis

• Market Cap: ¥26.77B
• Dividend Yield: N/A
• Average Volume (3M): 1.52M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.70
• Revenue Growth: -9.04%
• EPS Growth: 13.09%
• Country: JP
• Employees: 40
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -11.78
• Shares Outstanding: 29,291,600
• 10 Day Avg. Volume: 2,742,450
• 30 Day Avg. Volume: 1,517,566
• PEG Ratio: 0.23
• Price to Book (P/B): 4.11
• Price to Sales (P/S): 360.33
• P/FCF Ratio: -5.59
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: ¥1,072.00 ▲(17.16% Upside)

The overall stock score is primarily impacted by significant financial challenges, including declining revenues and persistent losses. While technical analysis shows positive momentum, the negative P/E ratio and lack of dividend yield weigh down the valuation score. The absence of earnings call and corporate events data means these factors do not influence the score.

Positive Factors

Strong Equity Position

A strong equity position indicates solid capitalization, providing a buffer against financial instability and supporting long-term growth initiatives.

Partnerships and Collaborations

Strategic partnerships can provide funding and shared resources, facilitating research and development and potentially accelerating product commercialization.

Innovative Product Focus

Focusing on innovative therapies in immuno-oncology positions the company to capitalize on growing demand for advanced cancer treatments, supporting long-term growth.

Negative Factors

Declining Revenues

Continued revenue decline poses a risk to financial sustainability and limits the company's ability to invest in growth and innovation.

Persistent Losses

Ongoing losses indicate challenges in achieving profitability, which can hinder long-term viability and investor confidence.

Negative Cash Flows

Negative cash flows from operations highlight financial strain, limiting the company's ability to fund operations and invest in future growth without external financing.

Oncolys BioPharma, Inc. Business Overview & Revenue Model

Company Description

Oncolys BioPharma Inc. engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. Its product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus that is in phase II clinical trial for the treatment of gastric cancer/gastroesophageal junction, head and neck, and esophageal cancers; and in phase I clinical trial for the treatment of hepatocellular carcinoma. The company's product pipeline also includes OBP-702, a telomerase-specific oncolytic adenovirus, which is in pre-clinical trial for the treatment of solid tumors; OBP-2011, which is in pre-clinical trial for the treatment of SARS-Cov-2 virus infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed the phase IIb clinical trial for the treatment of HIV infection; and OBP-801, a histone deacetylase inhibitor, which is in phase I clinical trial for the treatment of solid tumors, as well as in pre-clinical trial for ophthalmic use. In addition, it develops TelomeScan (OBP-401 and OBP-1101), a cancer detection drug, for detecting living circulating tumor cells in blood from cancer patients. Further, the company provides diagnostic drugs and inspection services. It has various licensing agreements with Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Oncolys BioPharma Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Oncolys BioPharma generates revenue primarily through the development and commercialization of its proprietary therapeutic products. This includes potential sales of its drugs post-approval, licensing agreements with larger pharmaceutical companies, and collaborations for joint development projects. The company may also receive milestone payments from partners as certain development and regulatory objectives are achieved. Significant partnerships with other biopharmaceutical firms can enhance its revenue streams, providing funding and shared resources for research and development efforts.

Oncolys BioPharma, Inc. Financial Statement Overview

Summary

Oncolys BioPharma, Inc. faces serious financial challenges characterized by declining revenues, persistent losses, and negative cash flows. While the balance sheet shows strong equity, the overarching issue is the inability to achieve profitability and positive cash flow, posing risks to long-term viability.

Income Statement

Oncolys BioPharma, Inc. has experienced significant revenue decline, with a drop from 2022 to 2023 and further to 2024. The company has consistently operated at a loss, with negative EBIT and net income margins, reflecting challenges in scaling profitable operations.

Balance Sheet

The company maintains a healthy equity position with a strong equity ratio, indicative of solid capitalization. However, the continued losses affect return on equity negatively. While debt levels are manageable, the lack of profitability is concerning for long-term stability.

Cash Flow

Operating and free cash flow have remained negative, indicating ongoing operational cash burn. Despite positive financing cash flow, likely from fundraising, the inability to generate positive cash flow from operations is a critical risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	28.55M	31.38M	63.04M	976.18M	642.49M	314.18M
Gross Profit	27.68M	31.38M	30.61M	338.49M	198.80M	236.11M
EBITDA	-2.18B	-1.68B	-1.93B	-1.14B	-1.60B	-2.08B
Net Income	-2.24B	-1.68B	-1.94B	-1.15B	-1.62B	-2.10B
Balance Sheet
Total Assets	1.93B	3.20B	2.04B	2.65B	4.29B	2.80B
Cash, Cash Equivalents and Short-Term Investments	1.39B	2.41B	1.53B	1.71B	3.45B	2.07B
Total Debt	377.04M	324.64M	315.17M	393.66M	503.47M	525.08M
Total Liabilities	493.35M	446.65M	566.50M	491.69M	697.88M	793.09M
Stockholders Equity	1.44B	2.75B	1.47B	2.16B	3.59B	2.00B
Cash Flow
Free Cash Flow	0.00	-2.02B	-1.34B	-1.72B	-1.74B	-1.47B
Operating Cash Flow	0.00	-2.02B	-1.34B	-1.72B	-1.74B	-1.47B
Investing Cash Flow	0.00	-4.71M	-5.39M	20.12M	-942.00K	-37.58M
Financing Cash Flow	0.00	2.88B	1.14B	-113.83M	3.09B	242.26M

Oncolys BioPharma, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 915.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4588, the sentiment is Neutral. The current price of 915 is below the 20-day moving average (MA) of 963.35, above the 50-day MA of 889.22, and above the 200-day MA of 689.11, indicating a neutral trend. The MACD of -18.95 indicates Positive momentum. The RSI at 46.16 is Neutral, neither overbought nor oversold. The STOCH value of 30.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4588.

Oncolys BioPharma, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4579	58 Neutral	¥25.70B	-29.68	―	―	9.87%	-24.41%
4588	52 Neutral	¥26.77B	-10.47	―	―	-9.04%	13.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4880	51 Neutral	¥7.71B	750.93	―	1.29%	-14.78%	-95.53%
4583	48 Neutral	¥7.28B	-7.96	―	―	25.28%	39.15%
4599	47 Neutral	¥15.80B	-8.75	―	―	―	11.34%
4888	45 Neutral	¥7.05B	-40.45	―	―	248.15%	76.92%

Oncolys BioPharma, Inc. Corporate Events

Oncolys BioPharma Reports Decline in Financial Performance for 2025

Oncolys BioPharma Inc. reported a decrease in net sales for the nine months ending September 30, 2025, with significant operating and ordinary losses compared to the previous year. The company’s financial position weakened, with a notable decline in total assets and net assets, reflecting ongoing challenges in its operations and market environment.